Gregor Wollensak1, Elena Iomdina. 1. Department of Ophthalmology, Martin-Luther-University, Halle, Germany. gwollens@hotmail.com
Abstract
PURPOSE: To strengthen rabbit sclera in vivo using chemical crosslinking with glyceraldehyde for a scleral-based treatment of progressive myopia. SETTING: Department of Ophthalmology, Martin-Luther-University, Halle, Germany. METHODS: Five chinchilla rabbits were treated with sequential sub-Tenon injections of 0.15 mL 0.5 M glyceraldehyde into the superonasal quadrant of the right eye 5 times during 14 days. The rabbits were humanely killed and biomechanical stress-strain measurements of scleral strips from the treatment area were performed and compared with nontreated contralateral control sclera using a microcomputer-controlled biomaterial tester. The treated eyes were examined histologically by light microscopy to exclude possible adverse effects. RESULTS: Following the crosslinking treatment, the ultimate stress was 15.8 MPa +/- 6.0 (SD) versus 3.1 +/- 0.3 MPa in the controls (increase of 409.7%; P<.02), the Young modulus was 129.6 +/- 53.7 MPa versus 11.5 +/- 1.8 MPa in the controls (increase of 1027%, P<.01), and ultimate strain was 19.8% +/- 2.6% MPA versus 38.2% +/- 5.1% MPA in the controls (decrease of 48.2% P<.05). Histologically, mild side effects were found in the peripheral cornea adjacent to the treatment area, with some inflammatory infiltrate and moderate loss of keratocytes. CONCLUSIONS: Glyceraldehyde crosslinking of scleral collagen increased the scleral biomechanical rigidity efficiently. Glyceraldehyde can be easily applied by sequential parabulbar injections. There were no side effects on the retina, so the new method might become a treatment modality for strengthening scleral tissue to prevent progressive myopia.
PURPOSE: To strengthen rabbit sclera in vivo using chemical crosslinking with glyceraldehyde for a scleral-based treatment of progressive myopia. SETTING: Department of Ophthalmology, Martin-Luther-University, Halle, Germany. METHODS: Five chinchilla rabbits were treated with sequential sub-Tenon injections of 0.15 mL 0.5 M glyceraldehyde into the superonasal quadrant of the right eye 5 times during 14 days. The rabbits were humanely killed and biomechanical stress-strain measurements of scleral strips from the treatment area were performed and compared with nontreated contralateral control sclera using a microcomputer-controlled biomaterial tester. The treated eyes were examined histologically by light microscopy to exclude possible adverse effects. RESULTS: Following the crosslinking treatment, the ultimate stress was 15.8 MPa +/- 6.0 (SD) versus 3.1 +/- 0.3 MPa in the controls (increase of 409.7%; P<.02), the Young modulus was 129.6 +/- 53.7 MPa versus 11.5 +/- 1.8 MPa in the controls (increase of 1027%, P<.01), and ultimate strain was 19.8% +/- 2.6% MPA versus 38.2% +/- 5.1% MPA in the controls (decrease of 48.2% P<.05). Histologically, mild side effects were found in the peripheral cornea adjacent to the treatment area, with some inflammatory infiltrate and moderate loss of keratocytes. CONCLUSIONS:Glyceraldehyde crosslinking of scleral collagen increased the scleral biomechanical rigidity efficiently. Glyceraldehyde can be easily applied by sequential parabulbar injections. There were no side effects on the retina, so the new method might become a treatment modality for strengthening scleral tissue to prevent progressive myopia.
Authors: Vijay Krishna Raghunathan; Sara M Thomasy; Peter Strøm; Bernardo Yañez-Soto; Shaun P Garland; Jasmyne Sermeno; Christopher M Reilly; Christopher J Murphy Journal: Acta Biomater Date: 2017-05-27 Impact factor: 8.947
Authors: MiJung Kim; Anna Takaoka; Quan V Hoang; Stephen L Trokel; David C Paik Journal: Invest Ophthalmol Vis Sci Date: 2014-04-10 Impact factor: 4.799
Authors: David C Paik; Quan Wen; Richard E Braunstein; Suzanna Airiani; Stephen L Trokel Journal: Invest Ophthalmol Vis Sci Date: 2008-10-03 Impact factor: 4.799
Authors: Matthew S Mattson; Joyce Huynh; Meredith Wiseman; Marco Coassin; Julia A Kornfield; Daniel M Schwartz Journal: Invest Ophthalmol Vis Sci Date: 2010-01-13 Impact factor: 4.799